Braidwell’s Avidity Biosciences RNAM Stock Holding History

Braidwell’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-331,907	Closed	-$14.5M	–	83
2025 Q3	$14.5M	Buy	+331,907	New	+$13.4M	0.43%	57

Other funds holding RNAM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Braidwell's RNAM Position: Q4 2025 in Review

Braidwell sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 331,907 shares — an estimated $14.5M sold.

Braidwell first reported a position in RNAM in Q3 2025 and held it in 1 quarter. The position peaked at $14.5M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

Braidwell reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
Braidwell sold 331,907 Avidity Biosciences shares in Q4 2025, an estimated $14.5M.
Braidwell first reported a position in Avidity Biosciences in Q3 2025 and held it in 1 quarter.
Braidwell's Avidity Biosciences position peaked at $14.5M in Q3 2025.
343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Braidwell's 13F filing for Q4 2025, filed 17 Feb 2026.